Fig. 5
From: Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
Prolonged survival of NCG mice with ovarian cancer cell xenograft tumors following intraperitoneal infusion of MSLN-CAR T cells. A Human ovarian tumor OVCAR3 cells were injected intraperitoneally into mice, following which 5 × 106 of either CD19-CAR T cells or MSLN-CAR T cells were injected intraperitoneally. Following treatment with the respective CAR T cells, tumor burden was monitored at the indicated time points using bioluminescent imaging. B Quantification of tumor bioluminescence levels at different time points (n = 6 mice per group). C Kaplan–Meier survival curve of NCG mice treated i.p. with CD19-CAR or MSLN-CAR T cells. The experiments were repeated twice, independently, with similar results. Statistical analysis by two-tailed log rank test; n.d., not detected; *P < 0.05